Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2011) 26 P198

ECE2011 Poster Presentations Pituitary (111 abstracts)

Effects on metabolic parameters after 12-month treatment with a new once-a-week sustained release recombinant growth hormone (LB03002) in adult patients with GH deficiency (GHD)

J Roemmler , A Gockel , B Otto , M Bidlingmaier & J Schopohl

Medizinische Klinik Innenstadt, Munich, Germany.

Introduction: GH substitution in GH deficiency (GHD) must be subcutaneously administered daily. Recently, a new sustained release formulation of GH (LB03002) has been developed which has to be injected only once per week. As a sub-study to the double-blind, randomized, placebo-controlled, multicenter, phase-III-study we performed this prospective study to evaluate influences of the new GH formulation on metabolic parameters and the hormones leptin and ghrelin in adult patients with GHD.

Methods: Eleven patients with GHD (4f/7m, median age 58 years (29–69 years)) without any GH therapy for at least 6 months were included in the study. Eight patients were treated with LB03002 for 12 months, three patients started with placebo for 6 months and were then switched to LB03002 for another 6 months. A 3 h oral glucose tolerance test (OGTT) was performed at study entry and at study end. Additionally, IGF1, lipid parameters including cholesterol, LDL, HDL, and triglycerides, leptin, ghrelin, HbA1c and C-peptide were measured. Body composition was evaluated by dual-energy-X-ray-absorptiometry, waist/hip (WHR) and waist/height (WHtR) ratio by tape.

Results: Multiple of upper limit of normal (xULN) of IGF1 (0.23 (0.09–0.4) vs 0.71 (0.4–1.04), P<0.01), WHR (0.98 (0.86–1.04) vs 1.01 (0.86–1.05), P<0.05) and ghrelin levels (119.8 ng/l (67.7–266.6) vs 137 ng/l (67–289.5), P<0.05) were significantly higher and fat mass (34.7% (20.4–49.2) vs 32.4% (16.7–48.5), P<0.05) and leptin levels (11.2 μg/l (3.3–55.7) vs (7.05 μg/l (2.4–54.3), P<0.05) were significantly lower at study end. Glucose and insulin levels during OGTT as well as insulin resistance (HOMA-IR), insulin sensitivity (ISI), β-cell function (HOMA-β), C-peptide and HbA1c were not statistically significantly different before and after GH substitution, neither were BMI, WHtR, bone-mineral-density (BMD) and lipid parameters.

Conclusion: Substitution with LB03002 showed statistically significant reduction of fat mass, which leads to reduced leptin levels and increased ghrelin levels but does not seem to influence glucose and lipid metabolism.

Article tools

My recent searches

No recent searches.